Symbols

ANRO

Alto Neuroscience·NYSE

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ANRO

Alto Neuroscience, Inc.

A clinical-stage biopharmaceutical company in California

Industry

Pharmaceutical

Established Date

03/25/2019

Listing Date

02/02/2024

Exchange

New York Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.altoneuroscience.com

Security Type

Common stock

Office address

650 Castro Street, Suite 450 Mountain View, CA 94041

Business

Introduction

Alto Neuroscience, Inc., was incorporated in Delaware on March 25, 2019. The company is headquartered in Los Altos, California. The company is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and efficient treatment options. Building on more than a decade of research by its founder, Dr. Amit Etkin, the company's goal is to gain insight into brain function and more effectively match patients with the right drugs by using treatments that target specific patient groups. The company's current product line includes five clinical-stage assets, initially targeting major depression (MDD) and schizophrenia populations with independent brain-based biomarkers. Each of the company's clinical stage product candidates has been evaluated through at least initial Phase 1 clinical trials and has been observed to be well tolerated. The company's most advanced programs, including two product candidates evaluated in ongoing late-stage (2b or later) trials, are supported by prospective repeating evidence of clinical activity in the biomarker signature population.

Company Financials

EPS

ANRO has released its 2025 Q3 earnings. EPS was reported at -0.52, versus the expected -0.64, beating expectations. The chart below visualizes how ANRO has performed over recent quarters, highlighting trends in earnings surprises.